Estimate the Levels of Copeptin and Chromogranin A and Some Biochemical Parameters in Patients with Chronic Diseases
Article Sidebar
Main Article Content
Abstract
The current study aimed to estimate the concentrations of copeptin and chromogranin A and some biochemical parameters in patients with chronic diseases. Eighty-five subjects reported different chronic diseases in Azadi Teaching Hospital and Al-Jumhuri Hospital from September 2023 to January 2024. Experimental work was carried out at the Laboratories of Al-Jumhuri Hospital in Kirkuk, Iraq. The volunteers in the current study were divided as follows: 30 healthy volunteers as a control group. 25 patients with chronic kidney disease. 30 patients with diabetes mellitus. 30 patients with heart failure diseases. The results showed some kidney functions in chronic kidney disease (CKD), diabetes mellitus (DM), and heart failure (HF) patients, where urea and creatinine levels in chronic kidney disease (CKD) patients significantly increased (P ≤ 0.05) compared to the control group. In DM patients and HF patients, the urea and creatinine levels showed non-significant (P > 0.05) change compared to the control group. CRP percentage in CKD patients was (52.0 %). DM patients and HF patients were (50.0 %) and (46.7 %), respectively, compared to the control group, which was (0.0 %). On the other hand, the results showed copeptin levels in CKD, DM, and heart failure patients were significantly (P ≤ 0.05) elevated compared to the control group. Chromogranin A (CgA) levels in CKD, DM, and heart failure patients significantly increased (P ≤ 0.05) compared to the control group. Based on the results of the current study, both copeptin and chromogranin A can be considered an important indicator in the diagnosis of some chronic diseases.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
1. Chaudhary P, Janmeda P, Docea AO, Yeskaliyeva B, Abdull Razis AF, Modu B, et al. Oxidative stress, free radicals and antioxidants: Potential crosstalk in the pathophysiology of human diseases. Frontiers in chemistry. 2023;11:1158198. https://doi.org/10.3389/fchem.2023.1158198
2. Priya C, Pracheta J. Quantification of phytochemicals and in vitro antioxidant activities from various parts of Euphorbia neriifolia Lin. J Appl Biol Biotechnol. 2022;10:1-4. https://dx.doi.org/10.7324/JABB.2022.100217
3. Bhatti JS, Sehrawat A, Mishra J, Sidhu IS, Navik U, Khullar N, et al. Oxidative stress in the pathophysiology of type 2 diabetes and related complications: Current therapeutics strategies and future perspectives. Free Radical Biology and Medicine.2022;184:114-34. https://doi.org/10.1016/j.freeradbiomed.2022.03.019
4. Marchio P, Guerra-Ojeda S, Vila J, Aldasoro M, Victor V, Mauricio M. Targeting early atherosclerosis: a focus on oxidative stress and inflammation. Oxid Med Cell Longev. 2019; 2019: 8563845. https://doi.org/10.1155/2019/8563845
5. Steven S, Frenis K, Oelze M, Kalinovic S, Kuntic M, Bayo Jimenez MT, et al. Vascular inflammation and oxidative stress: major triggers for cardiovascular disease. Oxidative medicine and cellular longevity. 2019;2019(1):7092151. https://doi.org/10.1155/2019/7092151
6. Bigagli E, Lodovici M. Circulating oxidative stress biomarkers in clinical studies on type 2 diabetes and its complications. Oxidative medicine and cellular longevity. 2019;2019(1):5953685. https://doi.org/10.3390%2Fantiox8030072
7. Ito F, Sono Y, Ito T. Measurement and clinical significance of lipid peroxidation as a biomarker of oxidative stress: oxidative stress in diabetes, atherosclerosis, and chronic inflammation. Antioxidants. 2019;8(3):72.
https://doi.org/10.1155/2019/5953685
8. Harris AR, McGivern P, Gilbert F, Van Bergen N. Defining Biomarkers in Stem Cell‐Derived Tissue Constructs for Drug and Disease Screening. Advanced Healthcare Materials. 2024:2401433. https://doi.org/10.1002/adhm.202401433
9. Nakov R, Snegarova V, Dimitrova-Yurukova D, Velikova T. Biomarkers in Irritable Bowel Syndrome: biological rationale and diagnostic value. Digestive Diseases. 2022;40(1): 23-32. https://doi.org/10.1159/000516027
10. Tan K, Sethi SK. Biomarkers in cardiorenal syndromes. Translational Research. 2014; 164(2): 122-34. https://doi.org/10.1016/j.trsl.2014.04.011
11. Broedbaek K, Hilsted L. Chromogranin A as biomarker in diabetes. Biomarkers in medicine. 2016;10(11):1181-9. https://doi.org/10.2217/bmm-2016-0091
12. Herold Z, Doleschall M, Kovesdi A, Patocs A, Somogyi A. Chromogranin A and its role in the pathogenesis of diabetes mellitus. Endokrynologia Polska.2018;69(5):598-610. https://doi.org/10.5603/ep.a2018.0052
13. Sánchez-Ospina D, Mas-Fontao S, Gracia-Iguacel C, Avello A, González de Rivera M, Mujika-Marticorena M, et al. Displacing the Burden: A Review of Protein-Bound Uremic Toxin Clearance Strategies in Chronic Kidney Disease. Journal of Clinical Medicine. 2024;13(5):1428. https://doi.org/10.3390/jcm13051428
14. Guyton A, Hall J. Micturition, diuretics and kidney diseases. Textbook of medical physiology. 1996:408-90.
15. Merzah KS, Hasson SF. The Biochemical changes in patients with chronic renal failure. Med Biol Sci. 2015;4(1):75-9.
16. EV. L. Approach to the patient with renal disease. Prim Care. 2008;35(2):94-183. DOI: 10.1016/j.pop.2008.02.001
17. Idonije BO, Festus O, Oluba OM. Plasma glucose, creatinine and urea levels in type 2 diabetic patients attending a Nigerian teaching hospital. 2011. http://dx.doi.org/10.3923/rjmsci.2011.1.3
18. Lalramenga P, Gupta S. Study of C-reactive protein significance in chronic kidney disease. 2019.
19. Pravin N, Jayashree S, Shilpa B, Suhas S, Jayashree S, Anand P. Study of serum uric acid and C-reactive protein levels in patients with chronic renal disease. Int J Biol Med Res. 2013;4(1):2758-61.
20. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Jama. 2001;286(3):327-34. https://doi.org/10.1001/jama.286.3.327
21. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes care. 2002;25(11):2016-21. https://doi.org/10.2337/diacare.25.11.2016
22. Ciardullo S, Zerbini F, Cannistraci R, Muraca E, Perra S, Oltolini A, et al. Differential association of sex hormones with metabolic parameters and body composition in men and women from the United States. Journal of Clinical Medicine.2023;12(14):4783. https://doi.org/10.3390/jcm12144783
23. Marques‐Vidal P, Bastardot F, von Känel R, Paccaud F, Preisig M, Waeber G, et al. Association between circulating cytokine levels, diabetes and insulin resistance in a population‐based sample (CoLaus study). Clinical endocrinology. 2013;78(2):232-41. https://doi.org/10.1111/j.1365-2265.2012.04384.x
24. Katan M, Morgenthaler N, Widmer I, Puder JJ, Konig C, Muller B, et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuroendocrinology Letters. 2008;29(3):341-6.
25. Zhu F-X, Wu H-L, Tu K-S, Chen J-X, Zhang M, Shi C. Serum levels of copeptin are associated with type 2 diabetes and diabetic complications in Chinese population. Journal of Diabetes and its Complications. 2016;30(8):1566-70. https://doi.org/10.1016/j.jdiacomp.2016.07.017
26. Asferg CL, Andersen U, Linneberg A, Goetze J, Jeppesen J. Copeptin, a surrogate marker for arginine vasopressin secretion, is associated with higher glucose and insulin concentrations but not higher blood pressure in obese men. Diabetic Medicine. 2014;31(6):728-32.
https://doi.org/10.1111/dme.12411
27. Bjornstad P, Johnson RJ, Snell-Bergeon JK, Pyle L, Davis A, Foster N, et al. Albuminuria is associated with greater copeptin concentrations in men with type 1 diabetes: a brief report from the T1D exchange Biobank. Journal of Diabetes and its Complications.2017;31(2):387-9. https://doi.org/10.1016/j.jdiacomp.2016.11.015
28. Maisel A, Xue Y, Shah K, Mueller C, Nowak R, Peacock WF, et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study. Circulation: heart failure. 2011;4(5):613-20. https://doi.org/10.1161/circheartfailure.110.960096
29. Pozsonyi Z, Förhécz Z, Gombos T, Karádi I, Jánoskuti L, Prohászka Z. Copeptin (C-terminal pro arginine-vasopressin) is an independent long-term prognostic marker in heart failure with reduced ejection fraction. Heart, Lung and Circulation. 2015;24(4):359-67. https://doi.org/10.1016/j.hlc.2014.10.008
30. Stoiser B, Mörtl D, Hülsmann M, Berger R, Struck J, Morgenthaler N, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. European journal of clinical investigation. 2006;36(11):771-8. https://doi.org/10.1111/j.1365-2362.2006.01724.x
31. Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. Journal of the American College of Cardiology. 2008;52(4):266-72. https://doi.org/10.1016/j.jacc.2008.03.050